A Faster Route to Antibody Peptide Maps - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Faster Route to Antibody Peptide Maps

  • November 18, 2026

  • 3 min

Share

Clinical Scorecard: A Faster Route to Antibody Peptide Maps

At a Glance

CategoryDetail
ConditionMonoclonal antibody peptide mapping and characterization
Key MechanismsRaPiD-mAb-MS combines 96-well sample preparation, automated nanoelectrospray direct infusion, high-resolution Orbitrap mass spectrometry, and software for peptide matching and modification analysis.
Target PopulationMonoclonal antibody researchers and development teams evaluating antibody sequences, modifications, formulations, or process conditions.
Care SettingAntibody discovery, formulation screening, and process development; regulated testing would require further method-specific qualification.

Key Highlights

  • The workflow processes 96 samples in approximately 1.5 to 2 hours; sample preparation takes about four hours.
  • Across more than 1,500 experiments involving 28 monoclonal antibody sequences, median sequence coverage was 100% and mean coverage was 97.7%.
  • The method detected oxidation, deamidation, glycosylation, terminal modifications, sequence variants, and antibody-drug conjugation sites.
  • Stable isotope-labeled peptides showed an average detection limit of approximately 0.7% relative abundance, varying from 0.2% to 1.2% by peptide.
  • The authors describe conventional LC-MS as important for ultratrace detection and established regulated quality-control workflows.

Guideline-Based Recommendations

Diagnosis

  • The article describes an analytical workflow for antibody peptide mapping, not a clinical diagnostic method.

Management

  • Use RaPiD-mAb-MS primarily for discovery, formulation screening, and process development, as positioned by the authors.
  • Retain conventional LC-MS for ultratrace detection and established regulated quality-control workflows.

Monitoring & Follow-up

  • The workflow can assess antibody sequence coverage and modifications including oxidation, deamidation, glycosylation, terminal modifications, sequence variants, and conjugation sites.
  • Oxidation measurements in forced-degradation studies correlated closely with conventional LC-MS results.

Risks

  • Detection sensitivity is lower than targeted LC-MS/MS can provide for some low-abundance species.
  • Deamidated peptides may overlap with unmodified counterparts and require high-resolution targeted MS/MS.
  • Isoaspartate is isobaric with aspartate and cannot be detected directly; the researchers used an optional enzymatic labeling step to create a measurable mass shift.
  • Further method-specific qualification is required before direct infusion can support regulated testing.

Patient & Prescribing Data

Not applicable; the article concerns laboratory analysis of monoclonal antibodies, not patient treatment.

No prescribing or treatment recommendations are reported.

Clinical Best Practices

  • Interpret detection limits in light of peptide-specific results, which ranged from 0.2% to 1.2% relative abundance.
  • Consider targeted MS/MS when deamidated and unmodified peptides overlap.
  • Use the optional enzymatic labeling step when assessing isoaspartate.
  • Do not assume the workflow is qualified for regulated testing; the authors state that further method-specific qualification is required.

Related Resources & Content

    Original Source(s)

    Related Content